ES2100136T3 - Omeprazol de magnesio. - Google Patents

Omeprazol de magnesio.

Info

Publication number
ES2100136T3
ES2100136T3 ES94921154T ES94921154T ES2100136T3 ES 2100136 T3 ES2100136 T3 ES 2100136T3 ES 94921154 T ES94921154 T ES 94921154T ES 94921154 T ES94921154 T ES 94921154T ES 2100136 T3 ES2100136 T3 ES 2100136T3
Authority
ES
Spain
Prior art keywords
omeprazol
magnesium
discovered
compound
preparation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES94921154T
Other languages
English (en)
Other versions
ES2100136T1 (es
Inventor
Lars Ake Kallstrom
Monica Annelie Nygren
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AstraZeneca AB
Original Assignee
AstraZeneca AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=20390588&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2100136(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by AstraZeneca AB filed Critical AstraZeneca AB
Publication of ES2100136T1 publication Critical patent/ES2100136T1/es
Application granted granted Critical
Publication of ES2100136T3 publication Critical patent/ES2100136T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Electroplating Methods And Accessories (AREA)
  • Conductive Materials (AREA)
  • Contacts (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Fats And Perfumes (AREA)
  • Glass Compositions (AREA)
  • Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
  • Powder Metallurgy (AREA)
  • Medicinal Preparation (AREA)

Abstract

SE DESCUBREN UNA NUEVA FORMA DE COMPUESTO DE OMEPRAZOL DE MAGNESIO UTIL EN LA ELABORACION DE FORMULACIONES FARMACEUTICAS, EL USO DEL PRODUCTO Y EL PROCESO PARA SU PRODUCCION.
ES94921154T 1993-07-09 1994-07-08 Omeprazol de magnesio. Expired - Lifetime ES2100136T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE19939302396A SE9302396D0 (sv) 1993-07-09 1993-07-09 A novel compound form

Publications (2)

Publication Number Publication Date
ES2100136T1 ES2100136T1 (es) 1997-06-16
ES2100136T3 true ES2100136T3 (es) 2002-09-01

Family

ID=20390588

Family Applications (1)

Application Number Title Priority Date Filing Date
ES94921154T Expired - Lifetime ES2100136T3 (es) 1993-07-09 1994-07-08 Omeprazol de magnesio.

Country Status (41)

Country Link
US (1) US5900424A (es)
EP (2) EP0707580B1 (es)
JP (2) JP3635432B2 (es)
KR (1) KR100353783B1 (es)
CN (1) CN1064680C (es)
AT (1) ATE212628T1 (es)
AU (1) AU679766B2 (es)
BR (1) BR9406940A (es)
CA (1) CA2166794C (es)
CZ (1) CZ288933B6 (es)
DE (2) DE707580T1 (es)
DK (1) DK0707580T3 (es)
DZ (1) DZ1792A1 (es)
EE (1) EE03127B1 (es)
EG (1) EG21437A (es)
ES (1) ES2100136T3 (es)
FI (1) FI114154B (es)
GR (1) GR970300015T1 (es)
HR (1) HRP940385B1 (es)
HU (1) HU226861B1 (es)
IL (1) IL110190A (es)
IS (1) IS2075B (es)
MA (1) MA23257A1 (es)
MX (1) MX9405217A (es)
MY (1) MY113274A (es)
NO (1) NO308702B1 (es)
NZ (1) NZ268693A (es)
PL (1) PL175999B1 (es)
PT (1) PT707580E (es)
RU (1) RU2139868C1 (es)
SA (1) SA94150058B1 (es)
SE (1) SE9302396D0 (es)
SG (1) SG52464A1 (es)
SI (1) SI0707580T1 (es)
SK (1) SK281230B6 (es)
TN (1) TNSN94079A1 (es)
TW (1) TW504509B (es)
UA (1) UA43343C2 (es)
WO (1) WO1995001977A1 (es)
YU (1) YU49193B (es)
ZA (1) ZA944933B (es)

Families Citing this family (95)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6875872B1 (en) 1993-05-28 2005-04-05 Astrazeneca Compounds
SE9301830D0 (sv) * 1993-05-28 1993-05-28 Ab Astra New compounds
SE9302395D0 (sv) * 1993-07-09 1993-07-09 Ab Astra New pharmaceutical formulation
SE9302396D0 (sv) * 1993-07-09 1993-07-09 Ab Astra A novel compound form
MX9700152A (es) * 1994-07-08 1997-04-30 Astra Ab Nueva formulacion farmaceutica oral, que contiene sal de magnesio de omeprazol.
PT1078628E (pt) 1994-07-08 2009-01-27 Astrazeneca Ab Forma de dosagem em comprimidos com unidades múltiplas
SE9500478D0 (sv) * 1995-02-09 1995-02-09 Astra Ab New pharmaceutical formulation and process
US6645988B2 (en) 1996-01-04 2003-11-11 Curators Of The University Of Missouri Substituted benzimidazole dosage forms and method of using same
US5840737A (en) 1996-01-04 1998-11-24 The Curators Of The University Of Missouri Omeprazole solution and method for using same
US6699885B2 (en) 1996-01-04 2004-03-02 The Curators Of The University Of Missouri Substituted benzimidazole dosage forms and methods of using same
US6489346B1 (en) * 1996-01-04 2002-12-03 The Curators Of The University Of Missouri Substituted benzimidazole dosage forms and method of using same
SE9600070D0 (sv) 1996-01-08 1996-01-08 Astra Ab New oral pharmaceutical dosage forms
SE508669C2 (sv) * 1996-04-26 1998-10-26 Astra Ab Nytt förfarande
US6623759B2 (en) 1996-06-28 2003-09-23 Astrazeneca Ab Stable drug form for oral administration with benzimidazole derivatives as active ingredient and process for the preparation thereof
TW385306B (en) * 1996-11-14 2000-03-21 Takeda Chemical Industries Ltd Method for producing crystals of benzimidazole derivatives
SE510666C2 (sv) * 1996-12-20 1999-06-14 Astra Ab Nya Kristallmodifikationer
SE9702000D0 (sv) * 1997-05-28 1997-05-28 Astra Ab New pharmaceutical formulation
US6747155B2 (en) 1997-05-30 2004-06-08 Astrazeneca Ab Process
SE510650C2 (sv) 1997-05-30 1999-06-14 Astra Ab Ny förening
US6174548B1 (en) 1998-08-28 2001-01-16 Andrx Pharmaceuticals, Inc. Omeprazole formulation
US6096340A (en) * 1997-11-14 2000-08-01 Andrx Pharmaceuticals, Inc. Omeprazole formulation
SE9704870D0 (sv) 1997-12-22 1997-12-22 Astra Ab New pharmaceutical formulation I
FR2774288B1 (fr) * 1998-01-30 2001-09-07 Ethypharm Sa Microgranules d'omeprazole gastroproteges, procede d'obtention et preparations pharmaceutiques
US6048981A (en) * 1998-04-22 2000-04-11 Torcan Chemical Ltd. Magnesium omeprazole and process for its preparation
DE19843413C1 (de) * 1998-08-18 2000-03-30 Byk Gulden Lomberg Chem Fab Neue Salzform von Pantoprazol
US6733778B1 (en) 1999-08-27 2004-05-11 Andrx Pharmaceuticals, Inc. Omeprazole formulation
SE9803772D0 (sv) 1998-11-05 1998-11-05 Astra Ab Pharmaceutical formulation
IL142703A (en) * 1998-11-10 2006-04-10 Astrazeneca Ab Crystalline form of omeprazole
UA72748C2 (en) 1998-11-10 2005-04-15 Astrazeneca Ab A novel crystalline form of omeprazole
IL142629A0 (en) * 1998-11-18 2002-03-10 Astra Ab Improved chemical process and pharmaceutical formulation
TWI243672B (en) 1999-06-01 2005-11-21 Astrazeneca Ab New use of compounds as antibacterial agents
US6316020B1 (en) * 1999-08-26 2001-11-13 Robert R. Whittle Pharmaceutical formulations
SE9903831D0 (sv) * 1999-10-22 1999-10-22 Astra Ab Formulation of substituted benzimidazoles
CA2290893C (en) * 1999-11-16 2007-05-01 Bernard Charles Sherman Magnesium omeprazole
DE19959419A1 (de) * 1999-12-09 2001-06-21 Ratiopharm Gmbh Stabile galenische Zubereitungen umfassend ein Benzimidazol und Verfahren zu ihrer Herstellung
SE0000774D0 (sv) 2000-03-08 2000-03-08 Astrazeneca Ab New formulation
CA2409258A1 (en) * 2000-05-15 2001-11-22 Ranbaxy Laboratories Limited Novel amorphous form of omeprazole salts
ATE342263T1 (de) 2000-08-04 2006-11-15 Takeda Pharmaceutical Salze von benzimidazol-derivaten und deren verwendung
CA2386716C (en) * 2002-05-17 2012-07-24 Bernard Charles Sherman Magnesium salt of s-omeprazole
US6544556B1 (en) 2000-09-11 2003-04-08 Andrx Corporation Pharmaceutical formulations containing a non-steroidal antiinflammatory drug and a proton pump inhibitor
WO2002026210A2 (en) * 2000-09-29 2002-04-04 Geneva Pharmaceuticals Inc. Proton pump inhibitor formulation
SE0101379D0 (sv) 2001-04-18 2001-04-18 Diabact Ab Komposition som hämmar utsöndring av magsyra
US8206741B2 (en) 2001-06-01 2012-06-26 Pozen Inc. Pharmaceutical compositions for the coordinated delivery of NSAIDs
SE0102993D0 (sv) 2001-09-07 2001-09-07 Astrazeneca Ab New self emulsifying drug delivery system
MXPA04007169A (es) * 2002-01-25 2004-10-29 Santarus Inc Suministro transmucosal de inhibidores de bomba de protones.
FR2836228B1 (fr) * 2002-02-21 2005-08-19 Inst Francais Du Petrole Methode et dispositif pour evaluer des parametres physiques d'un gisement souterrain a partir de debris de roche qui y sont preleves
US20030228363A1 (en) * 2002-06-07 2003-12-11 Patel Mahendra R. Stabilized pharmaceutical compositons containing benzimidazole compounds
SE0203065D0 (sv) 2002-10-16 2002-10-16 Diabact Ab Gastric acid secretion inhibiting composition
JP2006518751A (ja) * 2003-02-20 2006-08-17 サンタラス インコーポレイティッド 胃酸の急速かつ持続的な抑制のための新規製剤、オメプラゾール制酸剤複合体−即時放出物
US20070060556A1 (en) * 2003-05-05 2007-03-15 Yatendra Kumar Barium salt of benzimidazole derivative
US8993599B2 (en) * 2003-07-18 2015-03-31 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
TWI398273B (zh) * 2003-07-18 2013-06-11 Santarus Inc 用於抑制酸分泌之醫藥調配物及其製備及使用之方法
MXPA06000524A (es) * 2003-07-18 2006-08-11 Santarus Inc Formulacion farmaceutica y metodo para tratar desordenes gastrointestinales provocados por acido.
KR20060092255A (ko) 2003-09-26 2006-08-22 알자 코포레이션 고도의 약물적재를 제공하는 약물코팅제 및 그의 제조방법
RU2257890C2 (ru) * 2003-10-06 2005-08-10 Марио Атилио Лос Способ получения устойчивых фармацевтических композиций в форме таблеток, содержащих омепразол, и фармацевтические композиции, полученные таким способом
WO2005082888A1 (en) * 2004-03-01 2005-09-09 Milen Merkez Ilac Endustrisi A.S. Process for the preparation of magnesium salt of omeprazole
US8815916B2 (en) * 2004-05-25 2014-08-26 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
US8906940B2 (en) * 2004-05-25 2014-12-09 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
ES2246149B1 (es) * 2004-07-02 2007-06-01 Esteve Quimica, S.A. Formas solidas de la sal magnesica de s-omeprazol y procedimientos para su preparacion.
US20060024362A1 (en) 2004-07-29 2006-02-02 Pawan Seth Composition comprising a benzimidazole and process for its manufacture
US8541026B2 (en) 2004-09-24 2013-09-24 Abbvie Inc. Sustained release formulations of opioid and nonopioid analgesics
CN101111233A (zh) 2004-12-23 2008-01-23 兰贝克赛实验室有限公司 稳定的口服苯并咪唑组合物及其制备方法
US20060160783A1 (en) * 2004-12-30 2006-07-20 Transform Pharmaceuticals, Inc. Novel omeprazole forms and related methods
US20080279951A1 (en) * 2005-02-02 2008-11-13 Rajesh Gandhi Stable Oral Benzimidazole Compositions Prepared by Non-Aqueous Layering Process
US7981908B2 (en) 2005-05-11 2011-07-19 Vecta, Ltd. Compositions and methods for inhibiting gastric acid secretion
US7803817B2 (en) 2005-05-11 2010-09-28 Vecta, Ltd. Composition and methods for inhibiting gastric acid secretion
CA2624179A1 (en) * 2005-10-06 2007-04-12 Auspex Pharmaceuticals, Inc. Deuterated inhibitors of gastric h+, k+-atpase with enhanced therapeutic properties
EP1801110A1 (en) 2005-12-22 2007-06-27 KRKA, tovarna zdravil, d.d., Novo mesto Esomeprazole arginine salt
US7553857B2 (en) 2005-12-23 2009-06-30 Lek Pharmaceuticals D.D. S-omeprazole magnesium
CA2654402A1 (en) * 2006-06-01 2007-12-06 Adel Penhasi Multiple unit pharmaceutical formulation
AU2007278986B2 (en) 2006-07-25 2010-09-16 Vecta, Ltd. Compositions and methods for inhibiting gastric acid secretion using derivatives of small dicarboxylic acids in combination with PPI
US20090092658A1 (en) * 2007-10-05 2009-04-09 Santarus, Inc. Novel formulations of proton pump inhibitors and methods of using these formulations
WO2008067037A2 (en) 2006-10-05 2008-06-05 Santarus, Inc. Novel formulations of proton pump inhibitors and methods of using these formulations
WO2008057802A2 (en) 2006-10-27 2008-05-15 The Curators Of The University Of Missouri Compositions comprising at least one acid labile proton pump inhibiting agents, optionally other pharmaceutically active agents and methods of using same
EP1947099A1 (en) 2007-01-18 2008-07-23 LEK Pharmaceuticals D.D. Process for solvent removal from omeprazole salts
US8911787B2 (en) 2008-02-26 2014-12-16 Ranbaxy Laboratories Limited Stable oral benzimidazole compositions and process of preparation thereof
CN102015704A (zh) 2008-04-29 2011-04-13 霍夫曼-拉罗奇有限公司 Jnk的嘧啶基吡啶酮抑制剂
US20090280173A1 (en) * 2008-05-09 2009-11-12 Ishwar Chauhan Multilayer Omeprazole Tablets
US20090280175A1 (en) * 2008-05-09 2009-11-12 Ishwar Chauhan Multilayer Proton Pump Inhibitor Tablets
EP2147918A1 (en) 2008-07-21 2010-01-27 LEK Pharmaceuticals D.D. Process for the preparation of S-omeprazole magnesium in a stable form
AU2009290712A1 (en) 2008-09-09 2010-03-18 Astrazeneca Ab Method for delivering a pharmaceutical composition to patient in need thereof
WO2010122583A2 (en) 2009-04-24 2010-10-28 Rubicon Research Private Limited Oral pharmaceutical compositions of acid labile substances
CA2764963C (en) 2009-06-25 2016-11-01 Astrazeneca Ab Method for treating a patient at risk for developing an nsaid-associated ulcer
CN102638978A (zh) * 2009-06-25 2012-08-15 波曾公司 用于治疗需要阿司匹林治疗之患者的方法
WO2011080500A2 (en) 2009-12-29 2011-07-07 Orexo Ab New pharmaceutical dosage form for the treatment of gastric acid-related disorders
US20120294937A1 (en) 2009-12-29 2012-11-22 Novartis Ag New pharmaceutical dosage form for the treatment of gastric acid-related disorders
WO2011080502A2 (en) 2009-12-29 2011-07-07 Orexo Ab New pharmaceutical dosage form for the treatment of gastric acid-related disorders
EP2345408A3 (en) 2010-01-08 2012-02-29 Dr. Reddy's Laboratories Ltd. Acid labile drug formulations
EP2601947A1 (en) 2011-12-05 2013-06-12 Abo Bakr Mohammed Ali Al-Mehdar Fixed-dose combination for treatment of helicobacter pylori associated diseases
BR112014016085A8 (pt) 2011-12-28 2017-07-04 Pozen Inc composições aprimoradas e métodos para distribuição de omeprazol mais ácido acetilsalicílico
CN102993184A (zh) * 2013-01-08 2013-03-27 湖南方盛制药股份有限公司 一种埃索美拉唑及其镁盐三水合物的制备方法
EP3288556A4 (en) 2015-04-29 2018-09-19 Dexcel Pharma Technologies Ltd. Orally disintegrating compositions
WO2017145146A1 (en) 2016-02-25 2017-08-31 Dexcel Pharma Technologies Ltd. Compositions comprising proton pump inhibitors
US10076494B2 (en) 2016-06-16 2018-09-18 Dexcel Pharma Technologies Ltd. Stable orally disintegrating pharmaceutical compositions
EP4598528A1 (en) 2022-10-04 2025-08-13 Arsenil Zabirnyk Inhibition of aortic valve calcification

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE7804231L (sv) * 1978-04-14 1979-10-15 Haessle Ab Magsyrasekretionsmedel
SE8301182D0 (sv) * 1983-03-04 1983-03-04 Haessle Ab Novel compounds
GB2189698A (en) * 1986-04-30 1987-11-04 Haessle Ab Coated omeprazole tablets
DE4035455A1 (de) * 1990-11-08 1992-05-14 Byk Gulden Lomberg Chem Fab Enantiomerentrennung
SE9302396D0 (sv) * 1993-07-09 1993-07-09 Ab Astra A novel compound form

Also Published As

Publication number Publication date
DK0707580T3 (da) 2002-04-15
RU2139868C1 (ru) 1999-10-20
FI114154B (fi) 2004-08-31
JP3878826B2 (ja) 2007-02-07
US5900424A (en) 1999-05-04
SE9302396D0 (sv) 1993-07-09
MA23257A1 (fr) 1995-04-01
ATE212628T1 (de) 2002-02-15
WO1995001977A1 (en) 1995-01-19
FI960101L (fi) 1996-01-09
HU226861B1 (en) 2009-12-28
HK1008329A1 (en) 1999-05-07
TW504509B (en) 2002-10-01
CA2166794C (en) 1997-03-04
UA43343C2 (uk) 2001-12-17
KR100353783B1 (ko) 2004-04-03
TNSN94079A1 (fr) 1995-04-25
BR9406940A (pt) 1996-09-10
SI0707580T1 (en) 2002-06-30
DE707580T1 (de) 1997-09-04
CN1126993A (zh) 1996-07-17
DE69429774D1 (de) 2002-03-14
EP0707580A1 (en) 1996-04-24
IL110190A0 (en) 1994-10-21
GR970300015T1 (en) 1997-05-31
HRP940385B1 (en) 2003-06-30
HUT75314A (en) 1997-05-28
ES2100136T1 (es) 1997-06-16
EE03127B1 (et) 1998-10-15
EG21437A (en) 2001-10-31
SK2296A3 (en) 1996-10-02
SK281230B6 (sk) 2001-01-18
FI960101A0 (fi) 1996-01-09
AU7198194A (en) 1995-02-06
ZA944933B (en) 1995-02-20
IS4186A (is) 1995-01-10
AU679766B2 (en) 1997-07-10
HU9503873D0 (en) 1996-02-28
MY113274A (en) 2002-01-31
HRP940385A2 (en) 1997-02-28
EP1164132A2 (en) 2001-12-19
NO960068L (no) 1996-01-05
PT707580E (pt) 2002-06-28
EP0707580B1 (en) 2002-01-30
JPH08512315A (ja) 1996-12-24
JP3635432B2 (ja) 2005-04-06
DE69429774T2 (de) 2002-11-14
NZ268693A (en) 1997-05-26
YU43694A (sh) 1997-07-31
MX9405217A (es) 1995-01-31
NO960068D0 (no) 1996-01-05
IS2075B (is) 2005-12-15
CN1064680C (zh) 2001-04-18
CZ6996A3 (en) 1996-05-15
JP2002105072A (ja) 2002-04-10
PL175999B1 (pl) 1999-03-31
PL312440A1 (en) 1996-04-29
YU49193B (sh) 2004-09-03
SG52464A1 (en) 1998-09-28
CZ288933B6 (cs) 2001-09-12
IL110190A (en) 2000-07-26
DZ1792A1 (fr) 2002-02-17
EP1164132A3 (en) 2002-01-02
NO308702B1 (no) 2000-10-16
SA94150058B1 (ar) 2006-06-20

Similar Documents

Publication Publication Date Title
ES2100136T3 (es) Omeprazol de magnesio.
AR059764A2 (es) Proceso para preparar una composicion farmaceutica de ritonavir y composicion que se obtiene
MX9204268A (es) Una composicion para la liberacion prolongada y controlada de substancias medicamentosas y un proceso para preparar la misma.
AR004700A1 (es) 1alfa, 26 dihidroxi-d-homo-vitamina d3, una composicion farmaceutica que la comprende, un procedimiento para su preparacion y el uso de los mismos en laelaboracion de un medicamento
UY26372A1 (es) "imidazo-3-il-aminas bicíclicas procedimiento para su preparación y medicamentos que las contienen "
DE3461054D1 (en) Divisible tablet with sustained release of the active ingredient, and process for its production
CA2239174A1 (en) Novel compounds with analgesic effect
AR004510A1 (es) Composiciones que comprenden amoxicilina y clavulanato, procedimientos para su preparacion y el uso de las composiciones para la fabricacion de unmedicamento
MX9602683A (es) Compuestos de 6-dimetilaminometil-1-fenil-ciclohexano como substancias farmaceuticamente activas.
ES2191682T3 (es) Nueva formulacion farmaceutica.
FI942092A7 (fi) Hallitusti vapauttava valmiste
EP0279149A3 (en) Benzimidazole derivatives, process for their production and a pharmaceutical composition containing the same
AR029312A1 (es) Formas cristalinas de eto2c-ch2-(r)cgl-aze-pab-oh, procesos para su produccion, formulacion farmaceutica, y uso de estos compuestos para la elaboracion de un medicamento.
GB8904163D0 (en) Piperazine derivative or its sait,process for producing the same and pharmaceutical composition comprising the same as active ingredient
CA2227272A1 (en) Use of lipids as aids in the production of solid drug forms by melt extrusion
ES2144239T3 (es) Derivados de vitamina d con sustituyentes en c-25, procedimiento para su preparacion, productos intermedios y la utilizacion para la preparacion de medicamentos.
EP0360077A3 (de) Verwendung von Serotonin-Antagonisten bei der Behandlung von Apoplexia cerebri
ATE291908T1 (de) Ibuprofen-wirkstoffzubereitung
ES2193246T3 (es) Cefalosporinas antibacterianas.
IT8847871A0 (it) Ne e loro impiego come medicamenti derivati peptidici,loro preparazio-
ES2062137T3 (es) Utilizacion de 5'-deoxi-5'-metil-tioadenosina, s-adenosilmetionina y sus sales para la preparacion de composiciones farmaceuticas reductoras de seborrea.
ES2054718T3 (es) El uso de gepirona para la preparacion de una composicion farmaceutica para el tratamiento de la depresion atipica.
ZA911538B (en) New benzimidazole derivatives,process for their production and their pharmaceutical use
ES2191908T3 (es) 4-aminopirrol(3,2-d)pirimidinas como antagonistas del receptor del neuropeptido.
ES2111891T3 (es) Empleo de l-carnitina o acil l-carnitinas y valproato para tratar trastornos epilepticos.

Legal Events

Date Code Title Description
FC2A Grant refused

Effective date: 19960212

FG2A Definitive protection

Ref document number: 707580

Country of ref document: ES